biotechnology

Trinity Biotech received a Nasdaq non-compliance notice for failing to maintain minimum share value requirements. The company has 180 days to restore compliance or face delisting.

Eupraxia Pharmaceuticals raises $63.2M to advance its GI disease pipeline, including EP-104GI trials for eosinophilic esophagitis and other gastrointestinal indications.

4DMT will present pipeline progress at three major healthcare conferences in March 2026, showcasing late-stage programs including 4D-150 for retinal disease and 4D-710 for cystic fibrosis.

Elicio Therapeutics granted 30,300 stock options at $8.59 per share to a new employee on February 17, 2026, vesting over four years.

Maze Therapeutics CMO sold 15,000 shares via pre-arranged plan, completing divestiture. He retains 300,000 options while company maintains positive clinical momentum.

Trinity Biotech received a Nasdaq delisting warning after failing to maintain the $1.00 minimum bid price. The company has until August 2026 to restore compliance or face delisting.